• HOME
  • Universe A-Z
  • PSYCH STOCK NEWS
  • PSYCH NEWS
  • RESEARCH
  • TESTIMONIALS
  • CLINICAL TRIALS
  • CONFERENCES
  • 2024 PSYCHEDELIC INVESTOR CONFERENCE
Search
Psychedelic Stock Review

CLINICAL TRIALS

  • 2023 Watch List
  • 2024 WATCH LIST
  • ALCOHOL
  • CHARITY
  • CLIENT
  • CLINICAL TRIALS
  • CLINICS
  • CONFERENCES
  • DECK
  • INTERVIEW
  • INVESTORS
  • IPO
  • LARGE CAP PSYCH
  • NEO
  • PSYCH FUND | ETF
  • PSYCH NEWS
  • PSYCH STOCK NEWS
  • Psychedelic Investor Guide
  • Psychedelic Investor TV
  • RESEARCH
  • SIDE STORIES
  • STUFF
  • SUBSCRIBE
  • TESTIMONIALS
  • UNIVERSE
  • VETS
  • VIDEOS

    Silo Pharma (SILO) Takes Aim at $3.1 Billion Fibromyalgia Market.

    Editor | Curator - January 20, 2024

    Psycheceutial Biosciences (BWVI) Listed on WeFunder!

    Editor | Curator - November 1, 2023

    Seelos Falls of a Cliff on ‘Lesser Than Expected’ Results in...

    Editor | Curator - October 30, 2023

    Johns Hopkins Receives $20M From Roland R. Griffiths Ph.D. Professorship Fund...

    May 9, 2023

    Silo Pharma (SILO) Issues Letter to Shareholders

    December 2, 2022
    Silo Pharma, Psychedelic Stock Review, Psyilo

    Silo Pharma (SILO) $3.36 Achieves New Milestone for SP-26 Therapeutic -Initiates...

    November 11, 2022

    Silo Pharma (SILO) Attends Dawson James Conference.

    October 22, 2022
    Icannex

    Australian Icannex (IHL:ASX) Headed to NASDAQ?

    February 10, 2022

    Psychedelic Stock Review Initiates Coverage on Ehave Inc.

    October 2, 2021

    Small Pharma (DMTTF) Successfully Completes Phase I Clinical Trial Of DMT...

    September 21, 2021
    atai

    Huge News on Opioid Addiction From atai (ATAI).

    September 21, 2021

    Ehave (EHVVF) Announces Update On Ehave Medical App With The Launch...

    September 13, 2021
    Revive Therapeutics

    Revive Therapeutics (RVVTF) Provides Update on Psychedelics Clinical Product Pipeline

    August 11, 2021
    12Page 1 of 2
    ABOUT US
    FOLLOW US
    • About – Contact
    • Institutional Investors
    • Analysts
    • Side Stories
    • Disclaimer
    ©